Equities researchers at UBS Group initiated coverage on shares of Zoetis (NYSE:ZTS - Get Free Report) in a note issued to investors on Monday,Benzinga reports. The brokerage set a "neutral" rating and a $196.00 price target on the stock. UBS Group's price objective indicates a potential upside of 10.92% from the stock's current price.
ZTS has been the topic of several other reports. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, September 18th. Finally, BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $216.70.
Get Our Latest Analysis on ZTS
Zoetis Price Performance
NYSE:ZTS traded down $1.44 on Monday, hitting $176.71. The company had a trading volume of 1,646,209 shares, compared to its average volume of 2,541,524. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $79.73 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 2.88 and a beta of 0.89. The firm has a 50 day moving average of $181.72 and a two-hundred day moving average of $181.12.
Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the firm posted $1.36 earnings per share. The business's revenue for the quarter was up 11.6% on a year-over-year basis. On average, research analysts anticipate that Zoetis will post 5.9 earnings per share for the current year.
Institutional Investors Weigh In On Zoetis
A number of hedge funds have recently made changes to their positions in the business. State Street Corp lifted its stake in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock worth $2,030,813,000 after buying an additional 185,364 shares during the period. Mizuho Securities USA LLC grew its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after buying an additional 4,829,815 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company's stock valued at $812,695,000 after acquiring an additional 178,303 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after purchasing an additional 194,542 shares during the period. 92.80% of the stock is currently owned by institutional investors.
About Zoetis
(
Get Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
![Analyst Recommendations for Zoetis (NYSE:ZTS)](https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&Symbol=ZTS)
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.